Zimmer Biomet faces earnings test after emerging markets miss By Investing.com

NodeGuardian · 2026-02-23T17:50:37+00:00

Zimmer Biomet will report its Q4 earnings, focusing on international demand and innovation success after a past earnings miss. Analysts expect $2.40 EPS and $2.22 billion revenue, but the stock is near a 52-week low, reflecting mixed investor sentiment.

NodeGuardian

2026-02-23 17:50:37

Abstract generation in progress

Zimmer Biomet (NYSE: ZBH) is set to report its fourth-quarter earnings, with investors closely watching for signs of stabilized international demand and the success of its innovation pipeline after a prior earnings miss due to emerging markets weakness. Analysts project adjusted earnings of $2.40 per share and $2.22 billion in revenue, but the stock remains near its 52-week low amid divided Wall Street sentiment. The report will be critical for the company to regain investor confidence and establish credibility after a previous guidance cut.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.